Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis

Table 3 Severe and fatal infectious events with EGFR-MoAbs by specific types

	Infectious events, number/total, number		RR (95%CI)	Pvalue
	EGFR-MoAbs	Control	RR (95%CI)	Pvalue
Severe infections
Unspecified	236/2844	144/2829	1.57 (1.16 to 2.13)	0.004
Specified	365/7450	294/7347	1.18 (0.95 to 1.47)	0.14
Febrile neutropenia	287/4551	221/4579	1.09 (0.86 to 1.38)	0.68
Pneumonia	45/1605	37/1527	1.11 (0.72 to 1.70)	0.64
Sepsis	33/1294	6/1241	4.30 (1.80 to 10.27)	0.001
Fatal infections
Unspecified	8/1471	2/1424	2.39 (0.58 to 9.83)	0.23
Specified	16/2486	9/2305	1.43 (0.64 to 3.18)	0.38
Pneumonia	6/1336	3/1261	1.46 (0.39 to 5.48)	0.56
Febrile neutropenia	1/321	1/321	1.00 (0.11 to 9.51)	1.00
Sepsis	9/829	5/732	1.54 (0.50 to 4.74)	0.45

CI, confidence interval; EGFR, epidermal growth factor receptor; MoAbs, monoclonal antibodies; RR, relative risk.

ISSN: 1741-7015